Weight Watchers Weighs In On Obesity Drugs, Offering Valuable Validation

WW International’s decision to move into pharmaceutical weight management could build commercial momentum for Novo Nordisk’s Wegovy and Lilly’s Mounjaro.

Scale Weight
Weight Watchers is getting into the obesity drug space • Source: Shutterstock

Weight Watchers' decision to move into the new business area of facilitating access to obesity drugs could represent a commercial boon to manufacturers of the drugs like Novo Nordisk A/S and Eli Lilly and Company. Weight Watchers – with a subscriber base of 3.5 million individuals and a nearly 60-year heritage in weight management – is in a unique position to provide guidance to patients about how and when to use drug interventions to manage weight.

A high-profile consumer brand like Weight Watchers also offers validation about the value of new obesity medicines, a therapeutic area that has faced more challenges than most when it

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By 

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By 

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip